VIKTORIA-1 in Metastatic Breast Cancer

Drs. Wassim Mchayleh and Jason Mouabbi review findings from VIKTORIA-1 evaluating gedatolisib-based regimens after CDK4/6 inhibitor progression in HR-positive, HER2-negative metastatic breast cancer. They explain how dual targeting of the PI3K and mTOR pathways may provide an option for patients regardless of whether an actionable PIK3CA mutation is identified. The conversation compares gedatolisib plus fulvestrant with the addition of palbociclib, highlighting differences in progression-free survival, response rates, and toxicities such as neutropenia and stomatitis. They also consider how these regimens could fit into second-line treatment as additional endocrine and PI3K pathway targeted options enter clinical practice.